APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Orphan Drugs Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Orphan Drugs Service Market Outlook and Growth Opportunities 2026

Report ID 17420779042 May 2026191 pages

Choose your research edition.

Industry ResearchOrphan Drugs Service Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Orphan Drugs Service Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Orphan Drugs Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orphan Drugs Service Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Orphan Drugs Service Market Analysis and Forecast 2026-2032180 pages · $4,950 USD

Market perspective

The global Orphan Drugs Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Orphan Drugs Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Orphan Drugs Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Orphan Drugs Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Orphan Drugs Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Orphan Drugs Service market include Amgen, AstraZeneca, Cevidra, Johnson & Johnson, Medunik USA, Orphan Reach, OrphanDC, Sciensus and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Orphan Drugs Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Orphan Drugs Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orphan Drugs Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Orphan Drugs Service market.

Orphan Drugs Service Segment by Company

Amgen

AstraZeneca

Cevidra

Johnson & Johnson

Medunik USA

Orphan Reach

OrphanDC

Sciensus

Pfizer

Sanofi

Novartis

Roche

Celgene

BMS

Orphan Drugs Service Segment by Type

Congenital Disease

Genetic Disease

Tumors and Cancer

Chronic

Others

Orphan Drugs Service Segment by Application

Aldult

Children

Orphan Drugs Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Orphan Drugs Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Orphan Drugs Service key companies, revenue, market share, and recent developments.

3. To split the Orphan Drugs Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Orphan Drugs Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Orphan Drugs Service significant trends, drivers, influence factors in global and regions.

6. To analyze Orphan Drugs Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orphan Drugs Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orphan Drugs Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orphan Drugs Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Orphan Drugs Service industry.

Chapter 3: Detailed analysis of Orphan Drugs Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Orphan Drugs Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Orphan Drugs Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Orphan Drugs Service Industry Trends Table 2. Orphan Drugs Service Industry Drivers Table 3. Orphan Drugs Service Industry Opportunities and Challenges Table 4. Orphan Drugs Service Industry Restraints Table 5. Global Orphan Drugs Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Orphan Drugs Service Revenue Share by Company (2021-2026) Table 7. Global Orphan Drugs Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Orphan Drugs Service Key Company Manufacturing Base & Headquarters Table 9. Global Orphan Drugs Service Company, Product Type & Application Table 10. Global Orphan Drugs Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Orphan Drugs Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Congenital Disease Table 15. Significant Companies of Genetic Disease Table 16. Significant Companies of Tumors and Cancer Table 17. Significant Companies of Chronic Table 18. Significant Companies of Others Table 19. Global Orphan Drugs Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Orphan Drugs Service Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Orphan Drugs Service Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Orphan Drugs Service Sales Value Share by Type (2021-2026) Table 23. Global Orphan Drugs Service Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Aldult Table 25. Significant Companies of Children Table 26. Global Orphan Drugs Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Orphan Drugs Service Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Orphan Drugs Service Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Orphan Drugs Service Sales Value Share by Application (2021-2026) Table 30. Global Orphan Drugs Service Sales Value Share by Application (2027-2032) Table 31. Global Orphan Drugs Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Orphan Drugs Service Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Orphan Drugs Service Sales Value Share by Region (2021-2026) Table 34. Global Orphan Drugs Service Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Orphan Drugs Service Sales Value Share by Region (2027-2032) Table 36. Global Orphan Drugs Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Orphan Drugs Service Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Orphan Drugs Service Sales Value Market Share by Country (2021-2026) Table 39. Global Orphan Drugs Service Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Orphan Drugs Service Sales Value Market Share by Country (2027-2032) Table 41. Amgen Company Information Table 42. Amgen Business Overview Table 43. Amgen Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Amgen Orphan Drugs Service Product Portfolio Table 45. Amgen Recent Development Table 46. AstraZeneca Company Information Table 47. AstraZeneca Business Overview Table 48. AstraZeneca Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. AstraZeneca Orphan Drugs Service Product Portfolio Table 50. AstraZeneca Recent Development Table 51. Cevidra Company Information Table 52. Cevidra Business Overview Table 53. Cevidra Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Cevidra Orphan Drugs Service Product Portfolio Table 55. Cevidra Recent Development Table 56. Johnson & Johnson Company Information Table 57. Johnson & Johnson Business Overview Table 58. Johnson & Johnson Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Johnson & Johnson Orphan Drugs Service Product Portfolio Table 60. Johnson & Johnson Recent Development Table 61. Medunik USA Company Information Table 62. Medunik USA Business Overview Table 63. Medunik USA Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Medunik USA Orphan Drugs Service Product Portfolio Table 65. Medunik USA Recent Development Table 66. Orphan Reach Company Information Table 67. Orphan Reach Business Overview Table 68. Orphan Reach Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Orphan Reach Orphan Drugs Service Product Portfolio Table 70. Orphan Reach Recent Development Table 71. OrphanDC Company Information Table 72. OrphanDC Business Overview Table 73. OrphanDC Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. OrphanDC Orphan Drugs Service Product Portfolio Table 75. OrphanDC Recent Development Table 76. Sciensus Company Information Table 77. Sciensus Business Overview Table 78. Sciensus Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Sciensus Orphan Drugs Service Product Portfolio Table 80. Sciensus Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Pfizer Orphan Drugs Service Product Portfolio Table 85. Pfizer Recent Development Table 86. Sanofi Company Information Table 87. Sanofi Business Overview Table 88. Sanofi Orphan Drugs Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Sanofi Orphan Drugs Service Product Portfolio Table 90. Sanofi Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Orphan Drugs Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Novartis Orphan Drugs Service Product Portfolio Table 95. Novartis Recent Development Table 96. Roche Company Information Table 97. Roche Business Overview Table 98. Roche Orphan Drugs Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Roche Orphan Drugs Service Product Portfolio Table 100. Roche Recent Development Table 101. Celgene Company Information Table 102. Celgene Business Overview Table 103. Celgene Orphan Drugs Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Celgene Orphan Drugs Service Product Portfolio Table 105. Celgene Recent Development Table 106. BMS Company Information Table 107. BMS Business Overview Table 108. BMS Orphan Drugs Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. BMS Orphan Drugs Service Product Portfolio Table 110. BMS Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Orphan Drugs Service Product Image Figure 2. Global Orphan Drugs Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orphan Drugs Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Orphan Drugs Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Congenital Disease Image Figure 8. Genetic Disease Image Figure 9. Tumors and Cancer Image Figure 10. Chronic Image Figure 11. Others Image Figure 12. Global Orphan Drugs Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Orphan Drugs Service Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Orphan Drugs Service Sales Value Share by Type (2021-2032) Figure 15. Aldult Image Figure 16. Children Image Figure 17. Global Orphan Drugs Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Orphan Drugs Service Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Orphan Drugs Service Sales Value Share by Application (2021-2032) Figure 20. Global Orphan Drugs Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Orphan Drugs Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Orphan Drugs Service Sales Value (2021-2032) & (US$ Million) Figure 23. North America Orphan Drugs Service Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Orphan Drugs Service Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Orphan Drugs Service Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Orphan Drugs Service Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Orphan Drugs Service Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Orphan Drugs Service Sales Value (2021-2032) & (US$ Million) Figure 29. South America Orphan Drugs Service Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Orphan Drugs Service Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Orphan Drugs Service Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Orphan Drugs Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Congenital Disease
  • Genetic Disease
  • Tumors and Cancer
  • Chronic
  • Others
Applications
  • Aldult
  • Children
Companies covered
  • Amgen
  • AstraZeneca
  • Cevidra
  • Johnson & Johnson
  • Medunik USA
  • Orphan Reach
  • OrphanDC
  • Sciensus
  • Pfizer
  • Sanofi
  • Novartis
  • Roche
  • Celgene
  • BMS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Orphan Drugs Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Orphan Drugs Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Orphan Drugs Service Market Dynamics
  1. 2.1 Orphan Drugs Service Industry Trends
  2. 2.2 Orphan Drugs Service Industry Drivers
  3. 2.3 Orphan Drugs Service Industry Opportunities and Challenges
  4. 2.4 Orphan Drugs Service Industry Restraints
3 Orphan Drugs Service Market by Company
  1. 3.1 Global Orphan Drugs Service Company Revenue Ranking in 2025
  2. 3.2 Global Orphan Drugs Service Revenue by Company (2021-2026)
  3. 3.3 Global Orphan Drugs Service Company Ranking (2024-2026)
  4. 3.4 Global Orphan Drugs Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Orphan Drugs Service Company Product Type and Application
  6. 3.6 Global Orphan Drugs Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Orphan Drugs Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Orphan Drugs Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Orphan Drugs Service Market by Type
  1. 4.1 Orphan Drugs Service Type Introduction
  2. 4.1.1 Congenital Disease
  3. 4.1.2 Genetic Disease
  4. 4.1.3 Tumors and Cancer
  5. 4.1.4 Chronic
  6. 4.1.5 Others
  7. 4.2 Global Orphan Drugs Service Sales Value by Type
  8. 4.2.1 Global Orphan Drugs Service Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Orphan Drugs Service Sales Value by Type (2021-2032)
  10. 4.2.3 Global Orphan Drugs Service Sales Value Share by Type (2021-2032)
5 Orphan Drugs Service Market by Application
  1. 5.1 Orphan Drugs Service Application Introduction
  2. 5.1.1 Aldult
  3. 5.1.2 Children
  4. 5.2 Global Orphan Drugs Service Sales Value by Application
  5. 5.2.1 Global Orphan Drugs Service Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Orphan Drugs Service Sales Value by Application (2021-2032)
  7. 5.2.3 Global Orphan Drugs Service Sales Value Share by Application (2021-2032)
6 Orphan Drugs Service Regional Value Analysis
  1. 6.1 Global Orphan Drugs Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Orphan Drugs Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Orphan Drugs Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Orphan Drugs Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Orphan Drugs Service Sales Value (2021-2032)
  7. 6.3.2 North America Orphan Drugs Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Orphan Drugs Service Sales Value (2021-2032)
  10. 6.4.2 Europe Orphan Drugs Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Orphan Drugs Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Orphan Drugs Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Orphan Drugs Service Sales Value (2021-2032)
  16. 6.6.2 South America Orphan Drugs Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Orphan Drugs Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Orphan Drugs Service Sales Value Share by Country, 2025 VS 2032
7 Orphan Drugs Service Country-level Value Analysis
  1. 7.1 Global Orphan Drugs Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Orphan Drugs Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Orphan Drugs Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Orphan Drugs Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Orphan Drugs Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Orphan Drugs Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Orphan Drugs Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Orphan Drugs Service Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Orphan Drugs Service Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Cevidra
  14. 8.3.1 Cevidra Company Information
  15. 8.3.2 Cevidra Business Overview
  16. 8.3.3 Cevidra Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cevidra Orphan Drugs Service Product Portfolio
  18. 8.3.5 Cevidra Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Orphan Drugs Service Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Medunik USA
  26. 8.5.1 Medunik USA Company Information
  27. 8.5.2 Medunik USA Business Overview
  28. 8.5.3 Medunik USA Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Medunik USA Orphan Drugs Service Product Portfolio
  30. 8.5.5 Medunik USA Recent Developments
  31. 8.6 Orphan Reach
  32. 8.6.1 Orphan Reach Company Information
  33. 8.6.2 Orphan Reach Business Overview
  34. 8.6.3 Orphan Reach Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Orphan Reach Orphan Drugs Service Product Portfolio
  36. 8.6.5 Orphan Reach Recent Developments
  37. 8.7 OrphanDC
  38. 8.7.1 OrphanDC Company Information
  39. 8.7.2 OrphanDC Business Overview
  40. 8.7.3 OrphanDC Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 OrphanDC Orphan Drugs Service Product Portfolio
  42. 8.7.5 OrphanDC Recent Developments
  43. 8.8 Sciensus
  44. 8.8.1 Sciensus Company Information
  45. 8.8.2 Sciensus Business Overview
  46. 8.8.3 Sciensus Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sciensus Orphan Drugs Service Product Portfolio
  48. 8.8.5 Sciensus Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Orphan Drugs Service Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Orphan Drugs Service Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Orphan Drugs Service Product Portfolio
  66. 8.11.5 Novartis Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Roche Orphan Drugs Service Product Portfolio
  72. 8.12.5 Roche Recent Developments
  73. 8.13 Celgene
  74. 8.13.1 Celgene Company Information
  75. 8.13.2 Celgene Business Overview
  76. 8.13.3 Celgene Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Orphan Drugs Service Product Portfolio
  78. 8.13.5 Celgene Recent Developments
  79. 8.14 BMS
  80. 8.14.1 BMS Company Information
  81. 8.14.2 BMS Business Overview
  82. 8.14.3 BMS Orphan Drugs Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 BMS Orphan Drugs Service Product Portfolio
  84. 8.14.5 BMS Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst